NEW YORK, May 13 -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced that Richard Taney, President and Chief Executive Officer, will present at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference to be held from May 19-20 in Monte Carlo, Monaco. The Delcath presentation is scheduled for 11:20 AM Central European Summer Time on Tuesday, May 20, 2008.

This European conference is important as Delcath continues to expand awareness of the company's Percutaneous Hepatic Perfusion (PHP) technology and the clinical results of this innovative treatment for cancers in the liver. The Global Healthcare Conference is an opportunity to get the attention of new institutional investors, and to provide a forum for discussion with medical trade media outside of the U.S. Domestic interest in the System continues to increase following the recent release of updated results from a Phase II study of neuroendocrine tumors, which adds to the growing body of data indicating that Delcath's treatment is a viable option for patients diagnosed with inoperable liver tumors.

The presentation will be webcast live and can be accessed by visiting our website at www.delcath.com. The webcast will be archived for ninety days.

About Delcath Systems, Inc.
Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.